Related Experiment Videos
Single-dose activated charcoal-backup and reassess.
1Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232-4632, USA. donna.seger@vanderbilt.edu
Journal of Toxicology. Clinical Toxicology
|April 16, 2004
Summary
Single-dose activated charcoal (SDAC) is commonly given to poisoning patients, but evidence showing it improves outcomes is lacking. This review examines adverse events and the procedure's risk-benefit balance.
Area of Science:
- Emergency Medicine
- Clinical Toxicology
Background:
- Single-dose activated charcoal (SDAC) is a common intervention for poisoned patients.
- It is assumed to reduce toxin absorption and improve clinical outcomes.
- However, robust evidence supporting these benefits is often absent.
Purpose of the Study:
- To review reported adverse events associated with SDAC administration.
- To discuss the risk:benefit ratio of using SDAC in poisoning cases.
Main Methods:
- Literature review of adverse events following SDAC administration.
- Analysis of the risk-benefit profile of SDAC based on existing evidence.
Main Results:
- Evidence demonstrating that SDAC improves patient outcomes (morbidity and mortality) is lacking.
- Adverse events associated with SDAC administration have been reported.
- The overall risk:benefit ratio for SDAC in poisoning requires careful consideration.
Conclusions:
- The clinical benefit of SDAC in improving poisoning outcomes is not supported by current evidence.
- Potential risks and adverse events associated with SDAC administration should be carefully weighed against unproven benefits.